Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Crimmitschau – page 20

317 clinical trials in Crimmitschau, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Crimmitschau at a glance
317
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

317 trials in Crimmitschau

Open in trial search

Plasma cell myeloma

Not recruiting

Study on the Safety and Effectiveness of Teclistamab and Talquetamab for Patients with Newly Diagnosed Multiple Myeloma Eligible for Transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Plasma cell myeloma

Not recruiting

Study on Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed High-Risk Multiple Myeloma Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:University Medical Center Hamburg-Eppendorf

Study on Inupadenant, Carboplatin, and Pemetrexed for Adults with Metastatic Non-Small Cell Lung Cancer After Immunotherapy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Inupadenant Hydrochloride
  • Sponsor:iTeos Belgium

Study of Pembrolizumab with Lenvatinib after Chemoradiation Treatment in Patients with Locally Advanced Head and Neck Cancer who are PD-L1 Positive

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Universitaet Des Saarlandes

Comparison of Post-Transplant Cyclophosphamide versus Anti-T Lymphocyte Immunoglobulin for Prevention of Graft versus Host Disease in Patients Receiving Unrelated Donor Transplantation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:DKMS Group gGmbH

Major depression

Not recruiting

Study on the Effects of BH-200 (Nelivaptan) for Patients with Major Depressive Disorder

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nelivaptan
  • Sponsor:HMNC Holding GmbH

Study on the Effectiveness and Safety of Golcadomide and Rituximab for Patients with Newly Diagnosed Advanced Follicular Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Celgene Corp.

Malignant melanoma

Not recruiting

Study on Fianlimab and Cemiplimab for Adults with Resectable Stage III and IV Melanoma

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Breast cancer+4

Not recruiting

Study Comparing Ribociclib and Endocrine Therapy to Chemotherapy for Patients with Intermediate-Risk HR+/HER2- Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ribociclib
  • Sponsor:WSG Women's Cancer Study Group GmbH

Study of Galinpepimut-S compared to standard therapy for patients with acute myeloid leukemia who achieved complete remission after second-line treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Sellas Life Sciences Group Inc.

Plasma cell myeloma

Not recruiting

Comparison of intravenous versus subcutaneous isatuximab with lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma patients eligible for transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Rectal cancer

Not recruiting

Study Comparing FOLFOX Before Surgery to Risk-Adapted Chemotherapy After Surgery for Patients with Locally Advanced Rectal Cancer and Low Risk of Local Failure

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Heidelberg University

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Crimmitschau

What the registry says about research in the country

01 Dermatological Conditions

Research focusing on treatment options for atopic dermatitis, evaluating the effectiveness of methylprednisolone aceponate cream formulations in patients with mild to moderate symptoms.

  • Comparative effectiveness studies
  • Topical treatments
  • Anti-inflammatory therapies

Clinical assessments aim to enhance therapeutic options for skin inflammation management.

02 Fungal Skin Infections

Investigation of combination therapy using clotrimazole and betamethasone dipropionate for treating moderate to severe fungal skin infections, particularly focusing on candidiasis.

  • Antifungal treatments
  • Combined therapeutic approaches
  • Inflammatory control

Studies evaluate innovative treatment formulations for enhanced patient outcomes.

03 Facial Skin Disorders

Clinical evaluation of ivermectin-based treatments for papulopustular rosacea, comparing novel formulations with established therapies to reduce inflammatory lesions.

  • Rosacea management
  • Anti-inflammatory effects
  • Facial lesion reduction

Research focuses on improving therapeutic options for facial inflammatory conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.